Search

Your search keyword '"Sophie Guillemard"' showing total 11 results
Start Over Author "Sophie Guillemard"
11 results on '"Sophie Guillemard"'

1. Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean?

Author

Marie-Claude Eberlé, Cyril Fersing, Sophie Guillemard, Diana Ilonca, Séverine Guiu, and Emmanuel Deshayes

Subjects
bone scintigraphy, extraosseous uptake, lung uptake, SPECT/CT, Medicine (General), R5-920
Abstract

A 48-year-old woman was referred for a bone scan as an assessment of bone metastasis from breast cancer. Surprisingly, two hot spots of lung uptake were present in the left lung without any abnormality on CT slices. No history of pulmonary disease was observed. An optimized CT scan with fine slices performed the same day was strictly normal (without any micronodule). A lung ventilation/perfusion scintigraphy showed no significant perfusion defect. A follow-up bone scan performed eight months later was normal and without any lung uptake. After exclusion of the main etiologies described in the literature, such as amylosis, sarcoidosis, abscess, or hypercalcemia, radiotracer microembolism seems to be the most likely hypothesis in this patient.

Published
2022
Full Text
View/download PDF

2. Identification of 18F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer

Author

Deshayes, Thierry Galvez, Ikrame Berkane, Simon Thézenas, Marie-Claude Eberlé, Nicolas Flori, Sophie Guillemard, Alina Diana Ilonca, Lore Santoro, Pierre-Olivier Kotzki, Pierre Senesse, and Emmanuel

Subjects
malnutrition, 18F-FDG PET/CT, weight loss, brain metabolism, esophageal cancer
Abstract

18F-FDG PET-CT is routinely performed as part of the initial staging of numerous cancers. Other than having descriptive, predictive and prognostic values for tumors, 18F-FDG PET-CT provides full-body data, which could inform on concurrent pathophysiological processes such as malnutrition. To test this hypothesis, we measured the 18F-FDG uptake in several organs and evaluated their association with weight loss in patients at diagnosis of esophageal cancer. Forty-eight patients were included in this retrospective monocentric study. 18F-FDG uptake quantification was performed in the brain, the liver, the spleen, bone marrow, muscle and the esophageal tumor itself and was compared between patients with different amounts of weight loss. We found that Total Lesion Glycolysis (TLG) and peak Standardized Uptake Values (SUVpeak) measured in the brain correlated with the amount of weight loss: TLG was, on average, higher in patients who had lost more than 5% of their usual weight, whereas brain SUVpeak were, on average, lower in patients who had lost more than 10% of their weight. Higher TLG and lower brain SUVpeak were associated with worse OS in the univariate analysis. This study reports a new and significant association between 18F-FDG uptake in the brain and initial weight loss in patients with esophageal cancer.

Published
2023
Full Text
View/download PDF

3. Ureteropelvic junction obstruction with primary lymphoedema associated withCELSR1variants

Author

Murat Alpaslan, Sandrine Mestré-Godin, Aurélie Lay, Guido Giacalone, Raphaël Helaers, Salma Adham, Hélène Kovacsik, Sophie Guillemard, Erick Mercier, Laurence Boon, Nicole Revencu, Pascal Brouillard, Isabelle Quere, Miikka Vikkula, UCL - SSS/DDUV/GEHU - Génétique, and UCL - (SLuc) Service de chirurgie plastique

Subjects
Genetics, Genetics (clinical)
Abstract

BackgroundPrimary lymphoedema (PL) is a chronic, debilitating disease caused by developmental and functional defects of the lymphatic system. It is marked by an accumulation of interstitial fluid, fat and tissue fibrosis. There is no cure. More than 50 genes and genetic loci have been linked to PL. We sought to study systematically cell polarity signalling proteinCadherin Epidermal Growth Factor Laminin G Seven-pass G-type Receptor 1(CELSR1) variants linked to PL.MethodsWe investigated 742 index patients from our PL cohort using exome sequencing.ResultsWe identified nine variants predicted to causeCELSR1loss of function. Four of them were tested for nonsense-mediated mRNA decay, but none was observed. Most of the truncated CELSR1 proteins would lack the transmembrane domain, if produced. The affected individuals had puberty/late-onset PL on lower extremities. The variants had a statistically significant difference in penetrance between female patients (87%) and male patients (20%). Eight variant carriers had a kidney anomaly, mostly in the form of ureteropelvic junction obstruction, which has not been associated withCELSR1before.CELSR1is located in the 22q13.3 deletion locus of the Phelan-McDermid syndrome. As variable renal defects are often seen in patients with the Phelan-McDermid syndrome,CELSR1may be the long-sought gene for the renal defects.ConclusionPL associated with a renal anomaly suggests aCELSR1-related cause.

Published
2023
Full Text
View/download PDF

4. Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study

Author

Anne Fallières, Marie-Claude Eberlé, N. Flori, Hélène de Forges, Pierre Senesse, Julien Fraisse, Raphael Tetreau, Jean-Pierre Pouget, Sophie Guillemard, Pierre-Olivier Kotzki, Lore Santoro, Emmanuel Deshayes, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CRLCC Val d'Aurelle - Paul Lamarque, Unité de biostatistiques, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and CCSD, Accord Elsevier

Subjects
Blood Glucose, Male, 0301 basic medicine, medicine.medical_specialty, Cachexia, [SDV.CAN]Life Sciences [q-bio]/Cancer, 030209 endocrinology & metabolism, Carbohydrate metabolism, Critical Care and Intensive Care Medicine, Gastroenterology, Enteral administration, Eating, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Internal medicine, medicine, Humans, Prospective Studies, Nutritional support, Prospective cohort study, Aged, Cancer, Cancer staging, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, 030109 nutrition & dietetics, Nutrition and Dietetics, medicine.diagnostic_test, business.industry, Tumour growth, Middle Aged, medicine.disease, 3. Good health, Glucose, Parenteral nutrition, Head and Neck Neoplasms, Positron emission tomography, Female, (18)F-FDG PET/CT, business, Supportive care, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Summary Background & aims Nutrition support is recommended in cachexic patients with cancer. However, there is no clear evidence about its impact on tumour growth. Glycolysis, which is usually higher in cancer than normal cells, can be monitored by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging that is widely used for cancer staging and therapy efficacy assessment. Here, we used 18F-FDG PET/CT imaging to investigate whether artificial nutrition has an impact on tumour glucose metabolism in patients with cancer and cachexia. Methods This prospective study included ten patients with histologically proven head and neck or oesophageal cancer. All patients underwent 18F-FDG PET/CT imaging at baseline and after (parenteral and/or enteral) nutrition support on average for 7 days. Tumour glucose metabolism changes were evaluated using static (SUVmax, SUVmean and SULpeak) and dynamic (glucose metabolic rate and transport constant rates, k) parameters computed from the 18F-FDG PET/CT data. Results Artificial nutrition (median energy intake of 21.83 kcal/kg/day [13.16–45.90], protein intake of 0.84 g/kg/day [0.56–1.64]) was administered. Eight patients (80%) received enteral nutrition and two patients (20%) parenteral support. Comparison of 18F-FDG PET/CT parameters did not highlight any significant difference in tumour glucose metabolism before and after the period of nutrition support. Conclusions In cachexic patients with head and neck or oesophageal cancer, nutrition support administered according to the current guidelines shows no impact on tumour glucose metabolism, assessed by 18F-FDG PET/CT.

Published
2019
Full Text
View/download PDF

5. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18 F-Misonidazole PET/CT in Patients with Non–Small Cell Lung Carcinoma (RTEP5 Study)

Author

Romain Modzelewski, Mathieu Salaün, Fabrice Denis, Naji Salem, Pierre Bohn, Jean-Pierre Muratet, Pierre Olivier, Sophie Guillemard, Nicolas Aide, Enrique Chajon, Laurent Vervueren, Pierre Vera, Alina Berriolo Riedinger, Claire Houzard, Marie Lacombe, Françoise Mornex, Etienne Martin, Maximilien Vermandel, Nathalie Charrier, P.O. Kotzki, Frédéric Courbon, Anne Devillers, Véronique Beckendorf, S. Danhier, Carole Massabeau, Marc-André Mahé, Eric Dansin, P. Boisselier, Philippe Chaumet-Riffaud, Philippe Fernandez, Sébastien Thureau, Amaury Paumier, Marie-Pierre Farcy Jacquet, Hélène Kolesnikov-Gauthier, Amandine Pallardy, Sébastien Hapdey, Bernard Dubray, Service de médecine nucléaire [Rouen], CRLCC Haute Normandie-CRLCC Henri Becquerel, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service de Biophysique et de Médecine Nucléaire, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Therapies Interventionnelles Assistees Par l'Image et la Simulation, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Service de Médecine Nucléaire [Nantes], Hôpital Laennec, CRLCC René Gauducheau, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de médecine nucléaire [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Lab-STICC_UBO_CACS_MOCS, Université de Brest (UBO)-Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Centre Alexis Vautrin (CAV), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), CRLCC Eugène Marquis (CRLCC), Département de médecine nucléaire [Rennes], Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine nucléaire [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS), Centre Jean Bernard (ILC Le Mans), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), UNICANCER-Université Lille Nord de France (COMUE), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherches en Cancérologie de Toulouse (CRCT), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Cancérologie du GARD ICG - CHU Nîmes (Instit Cancéro - GARD), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CRLCC Paul Papin, Centre des Sciences de la Terre, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Département de radiothérapie et de physique médicale, CRLCC Henri Becquerel, Département de Radiothérapie, Centre René Gauducheau-Institut de Cancérologie de l'Ouest (ICO)-Centre de Lutte Contre le Cancer Nantes Atlantique 'René Gauducheau' (CLCC), Institut de cancérologie de l'Ouest - Nantes (ICO Nantes), CRLCC Paul Papin-CRLCC René Gauducheau, CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Radiation oncologie, CGFL, Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Department of Radiation Oncology, Centre Hospitalier Universitaire Lyon Sud, Pierre Benite, France

Subjects
Misonidazole, positron emission tomography, medicine.medical_treatment, Phases of clinical research, [SDV.CAN]Life Sciences [q-bio]/Cancer, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Carcinoma, medicine, Radiology, Nuclear Medicine and imaging, fluoro-deoxy-D-glucose, Lung cancer, Survival rate, Radiation oncologist, Pneumonitis, f-misonidasole, business.industry, hypoxia, medicine.disease, 3. Good health, radiotherapy dose, Radiation therapy, lung cancer, chemistry, 030220 oncology & carcinogenesis, business, Nuclear medicine
Abstract

International audience; See an invited perspective on this article on page 1043.This multicenter phase II study investigated a selective radiotherapy dose increase to tumor areas with significant (18)F-misonidazole ((18)F-FMISO) uptake in patients with non-small cell lung carcinoma (NSCLC). Methods: Eligible patients had locally advanced NSCLC and no contraindication to concomitant chemoradiotherapy. The (18)F-FMISO uptake on PET/CT was assessed by trained experts. If there was no uptake, 66 Gy were delivered. In (18)F-FMISO-positive patients, the contours of the hypoxic area were transferred to the radiation oncologist. It was necessary for the radiotherapy dose to be as high as possible while fulfilling dose-limiting constraints for the spinal cord and lungs. The primary endpoint was tumor response (complete response plus partial response) at 3 mo. The secondary endpoints were toxicity, disease-free survival (DFS), and overall survival at 1 y. The target sample size was set to demonstrate a response rate of 40% or more (bilateral α = 0.05, power 1-β = 0.95). Results: Seventy-nine patients were preincluded, 54 were included, and 34 were (18)F-FMISO-positive, 24 of whom received escalated doses of up to 86 Gy. The response rate at 3 mo was 31 of 54 (57%; 95% confidence interval [CI], 43%-71%) using RECIST 1.1 (17/34 responders in the (18)F-FMISO-positive group). DFS and overall survival at 1 y were 0.86 (95% CI, 0.77-0.96) and 0.63 (95% CI, 0.49-0.74), respectively. DFS was longer in the (18)F-FMISO-negative patients (P = 0.004). The radiotherapy dose was not associated with DFS when adjusting for the (18)F-FMISO status. One toxic death (66 Gy) and 1 case of grade 4 pneumonitis (>66 Gy) were reported. Conclusion: Our approach results in a response rate of 40% or more, with acceptable toxicity. (18)F-FMISO uptake in NSCLC patients is strongly associated with poor prognosis features that could not be reversed by radiotherapy doses up to 86 Gy.

Published
2017
Full Text
View/download PDF

6. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by

Author

Pierre, Vera, Sébastien, Thureau, Philippe, Chaumet-Riffaud, Romain, Modzelewski, Pierre, Bohn, Maximilien, Vermandel, Sébastien, Hapdey, Amandine, Pallardy, Marc-André, Mahé, Marie, Lacombe, Pierre, Boisselier, Sophie, Guillemard, Pierre, Olivier, Veronique, Beckendorf, Naji, Salem, Nathalie, Charrier, Enrique, Chajon, Anne, Devillers, Nicolas, Aide, Serge, Danhier, Fabrice, Denis, Jean-Pierre, Muratet, Etienne, Martin, Alina Berriolo, Riedinger, Helène, Kolesnikov-Gauthier, Eric, Dansin, Carole, Massabeau, Fredéric, Courbon, Marie-Pierre, Farcy Jacquet, Pierre-Olivier, Kotzki, Claire, Houzard, Francoise, Mornex, Laurent, Vervueren, Amaury, Paumier, Philippe, Fernandez, Mathieu, Salaun, and Bernard, Dubray

Subjects
Male, Observer Variation, Lung Neoplasms, Reproducibility of Results, Middle Aged, Sensitivity and Specificity, Survival Rate, Treatment Outcome, Carcinoma, Non-Small-Cell Lung, Humans, Tumor Hypoxia, Female, Dose Fractionation, Radiation, France, Misonidazole, Radiopharmaceuticals
Abstract

See an invited perspective on this article on page 1043.This multicenter phase II study investigated a selective radiotherapy dose increase to tumor areas with significant

Published
2016

7. Reverse myocardial and vascular uptake of in-111 pentetreotide in vasculitis

Author

Michel Rossi, Isabelle Serre, Michel Zanca, Jeanine Chevalier, Arnaud Bourdin, Sophie Guillemard, Sophie Riviere, Denis Mariano-Goulart, and Frédéric Comte

Subjects
Adult, Vasculitis, medicine.medical_specialty, medicine.diagnostic_test, Somatostatin receptor scintigraphy, business.industry, Anti-Inflammatory Agents, Heart, General Medicine, Neuroendocrine tumors, Pentetic Acid, medicine.disease, Scintigraphy, Adrenal Cortex Hormones, medicine, Humans, Radiology, Nuclear Medicine and imaging, Female, Radiology, Radionuclide Angiography, Radiopharmaceuticals, business
Abstract

Somatostatin receptor scintigraphy is habitually indicated in the evaluation of neuroendocrine tumors. We report the case of a 44-year-old woman with an unexpected vasculitis, which was detected on In-111 pentetreotide scintigraphy. Vascular uptake of the tracer was observed at presentation and disappeared after 3 months of corticotherapy.

Published
2006

8. Atypical lymphatic mapping in sentinel lymph node detection in breast cancer

Author

Tatiana Segard, Michel Rossi, Pierre-Ludovic Giacalone, and Sophie Guillemard

Subjects
Oncology, medicine.medical_specialty, Sentinel lymph node, Breast Neoplasms, Lymphatic mapping, Breast cancer, Internal medicine, medicine, Axillary nodes, Humans, Radiology, Nuclear Medicine and imaging, Drainage, Radionuclide Imaging, Aged, business.industry, Sentinel Lymph Node Biopsy, Carcinoma, General Medicine, medicine.disease, Trunk, Lymphatic system, Lymphatic Metastasis, Axilla, Female, Radiology, business
Abstract

Sentinel lymph node detection is applied widely for the management of breast cancer, and the external lymphoscintigraphy provides the surgeon with an accurate map of the lymphatic drainage. Although the most frequent drainage for breast cancer is toward the axillary nodes in 94%, various patterns have been described, especially in the internal mammary chain. In the literature, lymphatic drainage in breast cancer is usually limited to the trunk. We report an atypical case with drainage to an upper extremity.

Published
2006

9. Reversible rib photopenia demonstrated by bone scan in vaso-occlusive complication of systemic lupus erythematosus

Author

Tatiana Segard, Michel Rossi, Frédéric Comte, and Sophie Guillemard

Subjects
Adult, medicine.medical_specialty, Anemia, medicine.medical_treatment, Ribs, Technetium Tc 99m Medronate, Thrombophlebitis, hemic and lymphatic diseases, medicine, Humans, Lupus Erythematosus, Systemic, Radiology, Nuclear Medicine and imaging, Vascular Diseases, Radionuclide Imaging, Lupus anticoagulant, Rib cage, Lupus erythematosus, business.industry, General Medicine, medicine.disease, Surgery, Plasmapheresis, Female, Radiopharmaceuticals, Complication, business, Vaso-occlusive crisis
Abstract

We report the case of a 39-year-old woman with systemic lupus erythematosus (SLE), who was seen for excruciating rib pain, thrombocytopenia, anemia, renal failure, and an inflammatory syndrome. She was treated with high-dose steroids. A bone scan performed initially revealed upper thoracic cage photopenia and was suggestive of a vaso-occlusive crisis. At the same time, thrombophlebitis of the right arm was diagnosed. The presence of a lupus anticoagulant was highlighted. Plasmapheresis initiated 5 days after the bone scan relieved the patient immediately. A follow-up bone scan performed 20 days after the initial study showed improvement in uptake of the upper anterior ribs and confirmed the diagnosis of vaso-occlusive crisis.

Published
2006

10. Liste des auteurs

Author

Pierre, Abraham, Isabelle, Aïchoun, Jean-François, Auvert, Edgar, Balian, Marie-Thérèse, Barrellier, Michel, Bartoli, Jean-Michel, Baud, Patrice, Baudoin, François, Becker, Thomas, Behar, Laurence, Beyssier-Weber, Michèle, Bigorre, Sophie, Blaise, Gudrun, Böge, Christophe, Bonnin, Carine, Boulon, Dominique, Bravetti, Luc, Bressollette, Dominique, Brisot, Alexandra, Buffler, Patrick, Carpentier, Joël, Constans, Gérard, Coppé, Paul, Coulon, Marlène, Coupé, Antoine, Crémer, Michel, Dadon, Michel, Dauzat, Alberic, De Lambert, Véronique, Dehant, Emmanuel, Deshayes, Monika, Di Rienzo-Ambrozkiewicz, Antoine, Diard, Marie-Claude, Eberle, Antoine, Elias, Joseph, Emmerich, Nicolas, Falvo, Patrick, Faurous, François(†), Luizy, Catherine, Gaillard, Jean-Philippe, Galanaud, Pascal, Giordana, Philippe, Gosse, Nicolas, Grenier, Sophie, Guillemard, Jean-Louis, Guilmot, Christine, Jurus, Geneviève, Kercret, Van Kien Aurélie, Khau, Pierre-Olivier, Kotzki, Philippe, Lacroix, Georges, Lance, Jean-Pierre, Laroche, Yann, Le Bras, Claire, Le Hello, Georges, Leftheriotis, Philippe, Lemasle, Pierre-Édouard, Magnan, Sandrine, Mestre, Gilles, Miserey, Jacques, Monteil, Luc, Moraglia, Monira, Nou, Pierre, Ouvry, Antonia, Pérez-Martin, Gilles, Pernod, Olivier, Pichot, Jean-Noël, Poggi, Pascal, Priollet, Isabelle, Quéré, Marc, Righini, Jean-Claude, Saby, Santo, Saragosti, Gabrielle, Sarlon-Bartoli, Iris, Schuster-Beck, Jean-Michel, Serisé, Carmine, Sessa, Christophe, Seinturier, Marie-Antoinette, Sevestre-Pietri, Anne, Solanilla, Virginie, Soulier-Sotto, Muriel, Sprynger, Marc, Tapon, Béatrice, Terriat, Anne, Tissot, Laurent, Tribout, Hélène, Vernhet-Kovacsik, Alain, Viard, Stéphane, Vignes, and Denis, Wahl

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results